Presentation
Marine is a study engineer in the team of Mickaël Ménager.
She started working in September 2012 at Curie Institute as an assistant engineer in the team of Alain Nicolas "Recombination and Genetic Instability". She helped a doctoral student to study the mechanisms of meiotic recombination in yeast for a year. Then she worked for four years at Cochin Institute as a study engineer in the "Functional pharmacology and physiopathology of membrane receptors" team of Ralf Jockers. Her first project was to study the interaction between GPR50 and Nogo-A, a neuronal growth inhibitor. Then she worked on a project on Alzheimer's disease by studying the aggregation of Tau and Abeta proteins.
Since September 2017, Marine works under the direction of Mickaël Ménager on the understanding of the molecular mechanisms in the inflammatory response and the production of interferon. She brings her technical expertise on the TSPAN7 and CLOCK projects in collaboration with a postdoctoral fellow (Brieuc Pérot) and a doctoral student (Victor Garcia). She is also working on the protein HIF1A, a regulator of the metabolic switch in order to study its impact on the inflammatory response.
She helped set up the emerging Single Cell technology of 10X Genomics within the institute and is now the reference person for the preparation of the various libraries (scRNA-seq, scATAC-seq, CITE-seq, Spatial Transcriptomic) for the team and their various collaborators. Thanks to this technique, she works on auto-inflammatory diseases in order to study them at the transcriptomic level and better characterize them.
Resources & publications
-
Journal (source)J. Invest. Dermatol.
A TP63 mutation causes prominent alopecia with mild ectodermal dysplasia.
-
Journal (source)Br. J. Dermatol.
EBGene trial: patient preselection outcomes for the European GENEGRAFT ex viv...
-
Journal (source)Br. J. Dermatol.
EBGene trial: patient preselection outcomes for the European GENEGRAFT ex viv...
-
Journal (source)J. Invest. Dermatol.
Mutations in PERP Cause Dominant and Recessive Keratoderma.
-
Journal (source)Mol Ther Nucleic Acids
Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Usin...
-
Journal (source)Sci Transl Med
APOBEC mutation drives early-onset squamous cell carcinomas in recessive dyst...
-
Journal (source)J. Invest. Dermatol.
Intradermal Injection of Bone Marrow Mesenchymal Stromal Cells Corrects Reces...
-
Journal (source)J. Am. Acad. Dermatol.
Diacerein orphan drug development for epidermolysis bullosa simplex: A phase ...
-
Journal (source)J. Invest. Dermatol.
Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7)...
-
Journal (source)J. Invest. Dermatol.
Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fi...
-
Journal (source)J. Invest. Dermatol.
Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bull...
-
Journal (source)PLoS Genet.
KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
-
Journal (source)J. Exp. Med.
Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks...
-
Journal (source)J Allergy Clin Immunol
Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α a...
-
Journal (source)Expert Opin Emerg Drugs
Emerging drugs for the treatment of epidermolysis bullosa.
-
Journal (source)J Invest Dermatol
Drug Repurposing Reveals mTOR Inhibition as a Promising Strategy for Epidermo...